Analysts Conflicted on These Healthcare Names: Beta Bionics, Inc. (BBNX), Cormedix (CRMD) and Bolt Biotherapeutics (BOLT)
RBC Capital Reiterates Outperform on Cormedix, Maintains $12 Price Target
JMP Securities Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $19
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Cuts Target Price to $12
Rodman & Renshaw Maintains CorMedix(CRMD.US) With Buy Rating, Raises Target Price to $20
Needham Cuts CorMedix's Price Target to $12 From $18, Keeps Buy Rating
D. Boral Capital Maintains Buy on Cormedix, Maintains $15 Price Target
Cormedix Analyst Ratings
Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating
Truist Financial Remains a Buy on Cormedix (CRMD)
Leerink Partners Initiates CorMedix(CRMD.US) With Buy Rating, Announces Target Price $18
D. Boral Capital Maintains Buy on Cormedix, Maintains $15 Price Target
Cormedix Analyst Ratings
Cormedix Analyst Ratings
D. Boral Capital Initiates CorMedix(CRMD.US) With Buy Rating, Announces Target Price $15
Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating
Cormedix (CRMD) Receives a Buy From Truist Financial
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $18
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $18
Cormedix Buy Rating: Strong Sales Performance and Expanding Customer Base Signal Positive Growth Prospects